Johnson & Johnson Chief Scientific Officer Paul Stoffels, M.D., will retire at the end of the year, following the lead of CEO Alex Gorsky, who also departs soon. Emile Nuwaysir led Bayer's $1 billion bet on Parkinson's disease, and now he heads up gene therapy biotech Ensoma. Genentech's early cancer research leader Shiva Malek jumps to Novartis' NIBR oncology unit.